Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP)
OBiO Technology (Shanghai) Corp., Ltd.
As an academic conference laser-focusing on the oncolytic virus, this con-ference will invite 30+ leading scientists, enterprise executives, regulatory reviewers, consultants, and industry experts in the ﬁeld of oncolytic virus. The event aims to capture the trends and challenges in oncolytic virother-apy development and regulatory policies, exchanging the innovations and solutions in large-scale manufacturing, combination therapy, key clinical progress, and the future of commercialization. Through this hybrid event, we are bringing together experts worldwide and exploring the new breakthrough and possibilities of oncolytic virus therapy.
OBiO Technology (Shanghai) Corp., Ltd. (OBiO) is a gene and cell therapy-focused biotechnology company founded in 2013. In China for global customers, we offer holistic research, development, and manufacturing solutions for vectorology studies, functional genomics, process and analytical development, IND-enabling CMC, clinical and commercial manufacturing. "Enable gene therapy for better life" as our mission, we are committed to providing high-quality service to global customers, advancing your product from bench to clinic, and bringing benefit to populations around the world. For more information about OBiO, visit www.obiosh.com.